Venture capital plays a crucial role in scaling digital health innovations from promising prototypes to market-ready solutions. In recent years the flow of investment into telemedicine platforms, remote monitoring devices and AI-driven diagnostic tools has enabled entrepreneurs to build products that can be deployed across healthcare systems.
Investors are looking beyond flashy technology to businesses that can navigate regulatory pathways, demonstrate real clinical and economic value and sustain growth. The most successful startups often partner with healthcare providers early to validate their models, secure reimbursement and refine their go-to-market strategy. This discipline helps prevent the “pilot purgatory” that has trapped many digital health experiments.
At the same time, the size of funding rounds has increased as the market matures. Where a $1 million seed round once sufficed, companies now routinely raise tens of millions to develop data pipelines, pursue multi-country regulatory approvals and build enterprise-grade products. The rise of dedicated health-tech funds and corporate venture arms underscores the growing importance of digital health to the broader life sciences ecosystem.
This focus on thoughtful scaling aligns with themes explored in our earlier posts on why saving lives alone is not enough and whether Europe is ready for a digital health unicorn. Together these articles illustrate how investment, regulation and mindset must align for digital health ventures to thrive.
He has invested in startups including American Well, Neuronation, Mimi, and most notably mySugr – which was recently acquired by Roche. Min-Sung is also a contributing writer for mediums including TechCrunch and Tech.EU and studied Business Economics at Witten/Herdecke, Harvard, St.Gallen, and in Seoul.